Metabolomics Fingerprinting and Metabolic Dynamics After HIV Infection

Metabolic Fingerprintings and Metabolic Dynamics After HIV Infection:Impact of Metabolic Changes and Anti-Retroviral Therapy, Life Style and Clinical Conditions

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01828268

Enrollment

100

Registered

2013-04-10

Start date

2013-03-31

Completion date

2020-03-31

Last updated

2017-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV, Metabolomics Fingerprinting

Brief summary

The purpose of this plot study is to find out the relationship between metabolic changes and anti-retroviral therapy (ART), life style and clinical conditions of HIV-infected patients using nuclear magnetic resonance (NMR) based systems biology approach and metabolomics methodology.

Detailed description

Since the clinical application of anti-retroviral therapy (ART) in 1997, the life expectancy of HIV infected patients has been prolonged greatly. However,side effects of ART including metabolic abnormalities have become the main factors influencing patients' quality of life. Among which the abnormal lipid metabolism plays an important role. Meanwhile, metabolic conditions differ from patients applying to different combinations of ART drugs,life style and clinical conditions. Metabolomics can measure the dynamic metabolic responses of the body to stimuli or modifications. Using nuclear magnetic resonance (NMR) as tools can systematically analyse the process of lipid metabolism. Metabolomics fingerprinting can be defined as the complete complement of small molecule (\< 1500 Da) metabolites found in a specific cell, body fluid, organ or organism. Therefore, the study of the impact of metabolic changes and anti-retroviral therapy (ART), life style and clinical conditions is of importance in enhancing the adherence and improving the clinical outcomes of HIV infected patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of HIV infection

Exclusion criteria

* Pregnancy * Individual who is participating in other trial(s)

Design outcomes

Primary

Measure	Time frame
Dyslipidemia	Dyslipidemia events from admission to discharge(Up to 6 months) )

Secondary

Measure	Time frame
Lipoatrophy	Lipoarophy events from admission to discharge (up to 6 months)

Countries

China

Contacts

Primary ContactHua JIANG, PhD

hua.jiang@traumabank.org+86-28-88424391

Backup ContactBing CAI, Master

+86-28-88424391

Outcome results